Christina Psaros1, Jessica E Haberer, Elly Katabira, Allan Ronald, Elioda Tumwesigye, James D Campbell, Jonathan Wangisi, Kenneth Mugwanya, Alex Kintu, Michael Enyakoit, Katherine K Thomas, Deborah Donnell, Meighan Krows, Lara Kidoguchi, Norma Ware, Jared M Baeten, Connie Celum, David R Bangsberg, Steve A Safren. 1. *Department of Psychiatry, Massachusetts General Hospital Center, Boston, MA; †Harvard Medical School, Boston, MA; ‡Massachusetts General Hospital Center for Global Health, Boston, MA; §Infectious Disease Institute, Makerere University, Kampala, Uganda; ‖Department of Internal Medicine, University of Manitoba, Winnipeg, Canada; ¶Kabwohe Clinical Research Center, Kabwohe, Uganda; #Division of HIV/AIDS Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, US Centers for Disease Control and Prevention, Entebbe, Uganda; **Department of Epidemiology, University of Washington, Seattle, WA; ††Harvard School of Public Health, Boston, MA; ‡‡Infectious Diseases Institute, Makerere University College of Health Science, Kampala, Uganda; §§Department of Global Health, University of Washington, Seattle, WA; ‖‖Fred Hutchinson Cancer Research Center, Seattle, WA; ¶¶Departments of Global Health, Medicine, and Epidemiology, University of Washington, Seattle, WA; and ##Mbarara University of Science and Technology, Mbarara, Uganda.
Abstract
BACKGROUND:Daily preexposure prophylaxis (PrEP) is an effective HIV prevention strategy, but adherence is required for maximum benefit. To date, there are no empirically supported PrEP adherence interventions. This article describes the process of developing a PrEP adherence intervention and presents results on its impact on adherence. METHODS: The Partners PrEP Study was a placebo-controlled efficacy trial of daily oral tenofovir and emtricitabine/tenofovir PrEP among uninfected members of HIV-serodiscordant couples. An ancillary adherence study was conducted at 3 study sites in Uganda. Participants with <80% adherence as measured by unannounced pill count received an additional adherence counseling intervention based on Lifesteps, an evidence-based HIV treatment adherence intervention, based on principles of cognitive-behavioral theory. FINDINGS: Of the 1147 HIV-seronegative participants enrolled in the ancillary adherence study, 168 (14.6%) triggered the adherence intervention. Of participants triggering the intervention, 62% were men; median age was 32.5 years. The median number of adherence counseling sessions was 10. Mean adherence during the month before the intervention was 75.7% and increased significantly to 84.1% in the month after the first intervention session (P < 0.001). The most frequently endorsed adherence barriers at session 1 were travel and forgetting. INTERPRETATION: A PrEP adherence intervention was feasible in a clinical trial of PrEP in Uganda and PrEP adherence increased after the intervention. Future research should identify PrEP users with low adherence for enhanced adherence counseling and determine optimal implementation strategies for interventions to maximize PrEP effectiveness.
RCT Entities:
BACKGROUND: Daily preexposure prophylaxis (PrEP) is an effective HIV prevention strategy, but adherence is required for maximum benefit. To date, there are no empirically supported PrEP adherence interventions. This article describes the process of developing a PrEP adherence intervention and presents results on its impact on adherence. METHODS: The Partners PrEP Study was a placebo-controlled efficacy trial of daily oral tenofovir and emtricitabine/tenofovir PrEP among uninfected members of HIV-serodiscordant couples. An ancillary adherence study was conducted at 3 study sites in Uganda. Participants with <80% adherence as measured by unannounced pill count received an additional adherence counseling intervention based on Lifesteps, an evidence-based HIV treatment adherence intervention, based on principles of cognitive-behavioral theory. FINDINGS: Of the 1147 HIV-seronegative participants enrolled in the ancillary adherence study, 168 (14.6%) triggered the adherence intervention. Of participants triggering the intervention, 62% were men; median age was 32.5 years. The median number of adherence counseling sessions was 10. Mean adherence during the month before the intervention was 75.7% and increased significantly to 84.1% in the month after the first intervention session (P < 0.001). The most frequently endorsed adherence barriers at session 1 were travel and forgetting. INTERPRETATION: A PrEP adherence intervention was feasible in a clinical trial of PrEP in Uganda and PrEP adherence increased after the intervention. Future research should identify PrEP users with low adherence for enhanced adherence counseling and determine optimal implementation strategies for interventions to maximize PrEP effectiveness.
Authors: Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor Journal: Science Date: 2010-07-19 Impact factor: 47.728
Authors: Stephen G West; Naihua Duan; Willo Pequegnat; Paul Gaist; Don C Des Jarlais; David Holtgrave; José Szapocznik; Martin Fishbein; Bruce Rapkin; Michael Clatts; Patricia Dolan Mullen Journal: Am J Public Health Date: 2008-06-12 Impact factor: 9.308
Authors: D R Bangsberg; F M Hecht; E D Charlebois; A R Zolopa; M Holodniy; L Sheiner; J D Bamberger; M A Chesney; A Moss Journal: AIDS Date: 2000-03-10 Impact factor: 4.177
Authors: C Celum; A Wald; J R Lingappa; A S Magaret; R S Wang; N Mugo; A Mujugira; J M Baeten; J I Mullins; J P Hughes; E A Bukusi; C R Cohen; E Katabira; A Ronald; J Kiarie; C Farquhar; G J Stewart; J Makhema; M Essex; E Were; K H Fife; G de Bruyn; G E Gray; J A McIntyre; R Manongi; S Kapiga; D Coetzee; S Allen; M Inambao; K Kayitenkore; E Karita; W Kanweka; S Delany; H Rees; B Vwalika; W Stevens; M S Campbell; K K Thomas; R W Coombs; R Morrow; W L H Whittington; M J McElrath; L Barnes; R Ridzon; L Corey Journal: N Engl J Med Date: 2010-01-20 Impact factor: 91.245
Authors: Jessica H Oyugi; Jayne Byakika-Tusiime; Edwin D Charlebois; Cissy Kityo; Roy Mugerwa; Peter Mugyenyi; David R Bangsberg Journal: J Acquir Immune Defic Syndr Date: 2004-08-15 Impact factor: 3.731
Authors: Steven A Safren; Conall O'Cleirigh; Judy Y Tan; Sudha R Raminani; Laura C Reilly; Michael W Otto; Kenneth H Mayer Journal: Health Psychol Date: 2009-01 Impact factor: 4.267
Authors: Mark N Lurie; Brian G Williams; Khangelani Zuma; David Mkaya-Mwamburi; Geoff Garnett; Adriaan W Sturm; Michael D Sweat; Joel Gittelsohn; Salim S Abdool Karim Journal: Sex Transm Dis Date: 2003-02 Impact factor: 2.830
Authors: J Gerardo García-Lerma; Ron A Otten; Shoukat H Qari; Eddie Jackson; Mian-Er Cong; Silvina Masciotra; Wei Luo; Caryn Kim; Debra R Adams; Michael Monsour; Jonathan Lipscomb; Jeffrey A Johnson; David Delinsky; Raymond F Schinazi; Robert Janssen; Thomas M Folks; Walid Heneine Journal: PLoS Med Date: 2008-02 Impact factor: 11.069
Authors: Kenneth H Mayer; Steven A Safren; Steven A Elsesser; Christina Psaros; Jake P Tinsley; Mark Marzinke; William Clarke; Craig Hendrix; S Wade Taylor; Jessica Haberer; Matthew J Mimiaga Journal: AIDS Behav Date: 2017-05
Authors: Alexander Kintu; Susan E Hankinson; Raji Balasubramanian; Karen Ertel; Elioda Tumwesigye; David R Bangsberg; Jessica E Haberer Journal: J Acquir Immune Defic Syndr Date: 2015-05-01 Impact factor: 3.731
Authors: Tarisai Bere; Primrose Nyamayaro; Jessica F Magidson; Dixon Chibanda; Alfred Chingono; Ronald Munjoma; Kirsty Macpherson; Chiratidzo Ellen Ndhlovu; Conall O'Cleirigh; Khameer Kidia; Steven A Safren; Melanie Abas Journal: J Health Psychol Date: 2016-02-18
Authors: S Wade Taylor; Christina Psaros; David W Pantalone; Jake Tinsley; Steven A Elsesser; Kenneth H Mayer; Steven A Safren Journal: Cogn Behav Pract Date: 2017-02
Authors: Joseph Sila; Anna M Larsen; John Kinuthia; George Owiti; Felix Abuna; Pamela K Kohler; Grace John-Stewart; Jillian Pintye Journal: AIDS Patient Care STDS Date: 2020-08 Impact factor: 5.078
Authors: Steven M Goodreau; Deven T Hamilton; Samuel M Jenness; Patrick S Sullivan; Rachel K Valencia; Li Yan Wang; Richard L Dunville; Lisa C Barrios; Eli S Rosenberg Journal: J Adolesc Health Date: 2017-12-13 Impact factor: 5.012
Authors: Elizabeth C Pasipanodya; Sonia Jain; Xiaoying Sun; Jill Blumenthal; Eric Ellorin; Katya Corado; Michael P Dube; Eric S Daar; Sheldon R Morris; David J Moore Journal: J Infect Dis Date: 2018-10-05 Impact factor: 5.226